Department of Public Health, University of Naples Federico II, Naples, Italy.
Cytopathology. 2021 Sep;32(5):596-603. doi: 10.1111/cyt.12982. Epub 2021 May 6.
Over the past decade, immunotherapy has emerged as one of the most promising cancer treatments. Several monoclonal antibodies targeting the programmed death 1 (PD-1)/ programmed death ligand-1 (PD-L1) pathway have been integrated into standard-of-care treatments for a wide range of cancer types. Although all the available PD-L1 immunohistochemistry (IHC) assays have been developed on formalin-fixed histological specimens, a growing body of research has recently suggested the feasibility of PD-L1 testing on cytological samples. Although promising results have been reported, several important issues still need to be addressed. Among these are pre-analytical issues, cyto-hystological correlation, and inter-observer agreement. This review will briefly summarise the knowledge gaps and future directions of cytopathology in the immuno-oncology scenario.
在过去的十年中，免疫疗法已成为最有前途的癌症治疗方法之一。几种针对程序性死亡 1（PD-1）/程序性死亡配体 1（PD-L1）途径的单克隆抗体已被纳入多种癌症类型的标准治疗方法中。尽管所有现有的 PD-L1 免疫组织化学（IHC）检测方法都是在福尔马林固定的组织标本上开发的，但最近越来越多的研究表明在细胞学样本上进行 PD-L1 检测是可行的。尽管已经报道了有前途的结果，但仍有几个重要的问题需要解决。其中包括分析前问题、细胞组织学相关性和观察者间的一致性。这篇综述将简要总结免疫肿瘤学背景下细胞病理学的知识空白和未来方向。
